Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, discusses the efficiency of differentiation therapies for the elimination of acute myeloid leukemia at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH). Dr de Botton emphasizes the need to further improve results via the use of combination therapies, and describes how enasidenib can be combined with a wide variety of targeted drugs and other agents.
The potential of differentiation therapies for AML
